{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:32:18Z","timestamp":1794043938827,"version":"4.8.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","radiographyonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiography"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.radi.2026.103550","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:49:58Z","timestamp":1788256198000},"page":"103550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term efficacy and safety of helical tomotherapy for cholangiocarcinoma: A 10-year single-centre retrospective cohort study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5272-448X","authenticated-orcid":false,"given":"J.","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.radi.2026.103550_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: status quo, unmet needs and priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10272","key":"10.1016\/j.radi.2026.103550_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.radi.2026.103550_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"14","key":"10.1016\/j.radi.2026.103550_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.radi.2026.103550_bib5","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.radi.2026.103550_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.radi.2026.103550_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"5","key":"10.1016\/j.radi.2026.103550_bib8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.radi.2026.103550_bib9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00066-014-0714-1","article-title":"Stereotactic body radiotherapy for liver tumors","volume":"190","author":"Sterzing","year":"2014","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"10.1016\/j.radi.2026.103550_bib10","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1118\/1.596958","article-title":"Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy","volume":"20","author":"Mackie","year":"1993","journal-title":"Med Phys"},{"issue":"5","key":"10.1016\/j.radi.2026.103550_bib11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/jgh.12843","article-title":"Proton beam therapy for unresectable intrahepatic cholangiocarcinoma","volume":"30","author":"Ohkawa","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.radi.2026.103550_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis","volume":"34","author":"Tao","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.radi.2026.103550_bib13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"34","author":"Hong","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.radi.2026.103550_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.radi.2026.103550_bib16","series-title":"CTCAE and AE reporting - NCI","year":"2025"},{"issue":"991","key":"10.1016\/j.radi.2026.103550_bib17","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1259\/bjr\/31372149","article-title":"21 years of biologically effective dose","volume":"83","author":"Fowler","year":"2010","journal-title":"Br J Radiol"},{"issue":"6","key":"10.1016\/j.radi.2026.103550_bib18","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/jso.24946","article-title":"The prognostic impact of differentiation at the invasive front of biliary tract cancer","volume":"117","author":"Okubo","year":"2018","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.radi.2026.103550_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2011.05.016","article-title":"Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience","volume":"99","author":"Polistina","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radi.2026.103550_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1748-717X-7-67","article-title":"Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma","volume":"7","author":"Barney","year":"2012","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.radi.2026.103550_bib21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ajpath.2024.11.005","article-title":"Cholangiocarcinoma targeted therapies: mechanisms of action and resistance","volume":"195","author":"Ellis","year":"2025","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.radi.2026.103550_bib22","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radi.2026.103550_bib23","doi-asserted-by":"crossref","unstructured":"Tesini G., Greaves J., Knight O., Shand H., Ammirabile A., McHaffie S., et al.. IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers. JHEP Rep. 2026;101899. Published online May 20. doi:10.1016\/j.jhepr.2026.101899.","DOI":"10.1016\/j.jhepr.2026.101899"}],"container-title":["Radiography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078817426002269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078817426002269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:07:35Z","timestamp":1792768055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078817426002269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078817426002269"],"URL":"https:\/\/doi.org\/10.1016\/j.radi.2026.103550","relation":{},"ISSN":["1078-8174"],"issn-type":[{"value":"1078-8174","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety of helical tomotherapy for cholangiocarcinoma: A 10-year single-centre retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Radiography","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radi.2026.103550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The College of Radiographers. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103550"}}